Skip to main content

关于我们

Bio-Techne 为生命科学和临床诊断科研人员提供高质量的试剂、仪器、定制生产和检测服务。我们拥有一系列品牌,形成了独特的产品和服务组合。

我们对科学充满热忱;它推动我们合作、开发并生产屡获殊荣的工具,帮助研究人员实现可重现和一致的结果。无论您是处于学术研究的前沿、正将基础发现转化为治疗先导物,还是在需要最高诊断测试水平设备时,我们的创新产品和服务都能为您提供实现成功所需的解决方案。

Map of Bio-Techne headquarters and sites around the world
Bio-Techne Scientist

我们的承诺

致力于推进科学和技术,支持我们的产品。

提供全面支持,实施严格的质量控制,以确保高度的可靠性。

通过结合各学科和专业知识来提供整体解决方案,满足科学发现不断扩大的需求。

我们的历史

Bio-Techne Corporation Timeline

1976

Incorporated in Minnesota.

1976

R&D Systems founded.

1978

First R&D Systems product released.

1981

First 8-parameter blood control developed at R&D Systems.

1981

Techne Corporation incorporated in Minnesota.

1982

Tocris Neuramin (later known as Tocris Bioscience) founded.

1983

IPO as a blind pool (NASDAQ: TECH).

1984

Acquired General Diagnostics WBC Products.

1985

Acquired R&D Systems.

A biological products company founded in 1976.

1985

00

00

1985

R&D Systems established Growth Factor (now Biotechnology) division.

00

1985

R&D Systems marketed its first cytokine, TGF-beta 1, becoming the first company in the world to release this multifunctional protein.

1988

Released its first recombinant proteins.

1989

R&D Systems began developing monoclonal and polyclonal antibodies to cytokines.

1989

BiosPacific founded as a supplier of immunological reagents to the commercial diagnostic industry.

1990

Released first enzyme-linked immunosorbent assay (ELISA) through R&D Systems.

1991

Purchased Amgen’s research reagent and diagnostic assay kit business.

With this aquisition R&D Systems obtained its Erythropoietin kit, the first ELISA assay kit for a cytokine cleared by the FDA for clinical diagnostic use

1993

Established R&D Systems Europe, Ltd., in England.

1994

Tocris Neuramin merged with Cookson Chemicals, becoming Tocris Cookson Ltd.

1995

Established R&D Systems GmbH, in Germany.

1997

Boston Biochem founded to provide ubiquitin proteasome pathway researchers with tools facilitating drug discovery efforts.

1998

Acquired Genzyme Corp.’s research products business.

2002

Tocris Cookson awarded the Queen's Awards for Enterprise in the International Trade category.

2005

Acquired Fortron Bio Science, Inc.

A developer and manufacturer of monoclonal and polyclonal antibodies, antigens, and other biological reagents; Tocris Bioscience brand launched

2005

Acquired BiosPacific, Inc.

With 25 years of experience and well-qualified immunoreagents, BiosPacific supports the commercial diagnostic industry at every stage, from initial feasibility studies to large-scale manufacturing and production.

2006

Tocris Bioscience received multiple nominations for the prestigious Life Science Industry Awards.

2007

Established R&D Systems China Co., Ltd. in Shanghai China.

2011

Acquired Boston Biochem, Inc.

A leading developer and manufacturer of Ubiquitin-related biological products that facilitate basic research and drug discovery efforts

2011

Acquired Tocris Bioscience

Tocris is the leading supplier of biologically active molecules for life science research. Used in experiments to understand biological processes and diseases and as part of the initial drug-discovery process, Tocris life science reagents include receptor ligands, ion channel modulators, enzyme inhibitors, caged compounds, fluorescent probes, and screening libraries.

2011

Established R&D Systems Hong Kong Limited, in China

2013

Acquired Bionostics

A world-leading developer, manufacturer and distributor of quality turnkey products for OEMs in critical health care. The company specializes in calibration and quality control solutions, critical care/point-of-care and diabetes diagnostics test systems.

2014

New Trade Name, Bio-Techne, Announced.

Techne Corporation (NASDAQ: TECH) announced today that it will be operating under the new trade name, Bio-Techne. The use of Bio-Techne will bring the company’s R&D Systems, BiosPacific, Tocris Biosciences, Boston Biochem and Bionostics products under one common brand name. Techne Corporation Announces New Trade Name, Bio-Techne.

2014

Acquired ProteinSimple.

ProteinSimple develops and commercializes proprietary systems and consumables for protein analysis that ultimately help reveal new insights into the true nature of proteins. Their goal is to make protein analysis simpler, more quantitative and affordable. Their comprehensive portfolio of tools includes Simple Western systems that quantify protein expression and Biologics systems that probe the structure and purity of protein-based therapeutics.

June 17, 2014 Press Release

2014

Acquired Novus Biologicals, LLC

Novus Biologicals was founded in the summer of 1996 to license, produce and market antibodies to support niche and emerging areas of research. From Western blots on the kitchen table to a full lab and 200,000 plus antibodies and antibody-related products, we have come a long way from our niche antibody strategy. Novus is built on honesty, collaboration and strong relationships and will continue to provide quality tools to accelerate the bioscience research community.

July 2, 2014 Press Release

2014

Acquired CyVek, Inc.

CyVek has developed a transformative immunoassay technology, CyPlex™, which integrates an innovatively designed microfluidic cartridge with a state-of-the-art analyzer to deliver the most advanced and efficient bench top immunoassay system. CyPlex's ability to provide “sample to answer” test results precisely and quickly in a sealed disposable device makes it a very attractive platform for both research and clinical applications. The CyPlex technology has the potential for broad market applicability.

November 4, 2014 Press Release

2015

Acquired Cliniqa Corporation

2016

Acquired Zephyrus Biosciences, Inc.

2016

Acquires Space Import-Export and Strengthens European Leadership Team

2016

Announces Agreement to Acquire Advanced Cell Diagnostics

2017

Acquires Trevigen, Inc.

2018

Acquires Atlanta Biologicals, Inc.

2018

Acquires Eurocell Diagnostics

EUROCELL has been a valued partner of Bio-Techne since 2004, selling R&D Systems hematology products in Europe, Africa and the Middle East (EMEA). EUROCELL Diagnostics is located close to Rennes in FRANCE; its mission is to sale Diagnostics Division products by offering to our customers its whole catalog in the fields of hematology, chemistry, immunology and measurement of blood gases.

2018

Acquires Quad Technologies

2018

Acquires Exosome Diagnostics, Inc.

2019

Acquires Access to B-MoGen Biotechnologies' Gene Editing Technology

2021

Completes acquisition of Asuragen, Inc.

2022

Completes Namocell acquisition

2023

Completes Lunaphore acquisition

 
Incorporated in Minnesota.
1976

Incorporated in Minnesota.

R&D Systems founded.

First R&D Systems product released.

First 8-parameter blood control developed at R&D Systems.

Techne Corporation incorporated in Minnesota.

Tocris Neuramin (later known as Tocris Bioscience) founded.

IPO as a blind pool (NASDAQ: TECH).

Acquired General Diagnostics WBC Products.

Acquired R&D Systems.

00

R&D Systems established Growth Factor (now Biotechnology) division.

R&D Systems marketed its first cytokine, TGF-beta 1, becoming the first company in the world to release this multifunctional protein.

Released its first recombinant proteins.

R&D Systems began developing monoclonal and polyclonal antibodies to cytokines.

BiosPacific founded as a supplier of immunological reagents to the commercial diagnostic industry.

Released first enzyme-linked immunosorbent assay (ELISA) through R&D Systems.

Purchased Amgen’s research reagent and diagnostic assay kit business.

Established R&D Systems Europe, Ltd., in England.

Tocris Neuramin merged with Cookson Chemicals, becoming Tocris Cookson Ltd.

Established R&D Systems GmbH, in Germany.

Boston Biochem founded to provide ubiquitin proteasome pathway researchers with tools facilitating drug discovery efforts.

Acquired Genzyme Corp.’s research products business.

Tocris Cookson awarded the Queen's Awards for Enterprise in the International Trade category.

Acquired Fortron Bio Science, Inc.

Acquired BiosPacific, Inc.

Tocris Bioscience received multiple nominations for the prestigious Life Science Industry Awards.

Established R&D Systems China Co., Ltd. in Shanghai China.

Acquired Boston Biochem, Inc.

Acquired Tocris Bioscience

Established R&D Systems Hong Kong Limited, in China

Acquired Bionostics

New Trade Name, Bio-Techne, Announced.

Acquired ProteinSimple.

Acquired Novus Biologicals, LLC

Acquired CyVek, Inc.

Acquired Cliniqa Corporation

Acquired Zephyrus Biosciences, Inc.

Acquires Space Import-Export and Strengthens European Leadership Team

Announces Agreement to Acquire Advanced Cell Diagnostics

Acquires Trevigen, Inc.

Acquires Atlanta Biologicals, Inc.

Acquires Eurocell Diagnostics

Acquires Quad Technologies

Acquires Exosome Diagnostics, Inc.

Acquires Access to B-MoGen Biotechnologies' Gene Editing Technology

Completes acquisition of Asuragen, Inc.

Completes Namocell acquisition

Completes Lunaphore acquisition

1850
1860
1870
1880
1890
1900
1910
1920
1930
1940
1950
1960
1970
1980
1990
2000
2010
2020
2030
2040
2050
2060
2070
2080
2090
2100
2110
2120
2130
1964
1965
1966
1967
1968
1969
1971
1972
1973
1974
1975
1976
1977
1978
1979
1981
1982
1983
1984
1985
1986
1987
1988
1989
1991
1992
1993
1994
1995
1996
1997
1998
1999
2001
2002
2003
2004
2005
2006
2007
2008
2009
2011
2012
2013
2014
2015
2016
2017
2018
2019
2021
2022
2023
2024
2025
2026
2027
2028
2029
2031
2032
2033
2034

美国中西部起源

生物制品公司 R&D Systems 位于明尼苏达州,最初生产血液学质控品和校准品供医院和诊所使用。1977 年推出了我们的首款产品——富血小板血浆质控品,并于 1981 年成为全球第二家发布含血小板的全血质控品的制造商。多年来,临床质控品部门(原 R&D Systems 血液学)继续开发各种血液学质控品。然而,在 20 世纪 80 年代早期,R&D Systems 的工作人员注意到,血小板中有一种具有多种有趣特性的生长因子。从那时起,我们开始关注生产生长因子试剂供研究人员使用的可能性。

Former Land O'Lakes factory circa 1927 and current Bio-Techne headquarters.
Former Land O'Lakes factory circa 1927 and current Bio-Techne headquarters.

R&D Systems 进入生物技术市场

1985 年,我们发布了第一款研究试剂 TGF-β1,成为世界上首家商业生产这种细胞因子的公司。TGF-β1 是一种细胞外信号分子,由多种细胞产生。它参与免疫功能、细胞增殖和细胞分化等过程。该产品上市后,我们对天然来源的几种其他细胞因子进行纯化,并将其投放到研究市场。细胞因子是能在细胞间传递信息的特殊蛋白质,对于生物医学研究人员具有重大意义。它们有多种生物活性,包括调节发育过程和协调免疫应答。此外,许多疾病(包括癌症、心血管疾病和炎症性疾病)都与细胞因子活性失调有关。

我们在细胞因子市场取得了成功,并在此推动下,于 1985 年成立了生长因子(现在称为生物技术)部门,目标是通过基因工程生产和营销多种人类细胞因子。与从天然来源提取这些蛋白质相比,重组 DNA 技术具有几项优势,包括生产成本更低、可能实现无限量供应等。1989 年,生物技术部开始开发细胞因子的单克隆和多克隆抗体;1990 年,我们开发了首个酶联免疫吸附测定法 (ELISA) 试剂盒。

1991 年,我们收购了 Amgen 的生物制剂和 Dx 业务,并因此获得了美国食品药品监督管理局 (FDA) 批准的首个用于临床诊断的细胞因子 ELISA 检测试剂盒。1998 年,我们收购了健赞公司 (Genzyme Corporation) 的研究产品业务。此次收购使我们成为世界领先的研究和诊断细胞因子产品供应商。

TGF-Beta 1 protein

R&D Systems 产品 TGF-β1 的带状结构。

拓展到新市场

在 20 世纪 90 年代,我们把重点转向扩大销售和分销网络。我们收购了 British Bio-technology Products Ltd.,并将其定为我们在欧洲的首家分销商,将集团名称更名为 R&D Systems Europe, Ltd。R&D Systems Europe 在欧洲、非洲和中东地区销售和分销公司的生物技术产品。由于欧洲市场的增长,我们于 1995 年在德国开设了一家销售办事处 R&D Systems GmbH。2007 年,R&D Systems 在中国成立全资子公司,并于当年晚些时候在上海开设仓库和配送中心。该子公司为不断增长的中国市场提供仓储、营销、销售和技术服务。2011 年,RD &Systems China 在中国香港建立了一家销售子公司。

我们还完成了多次战略性收购。2005 年,R&D Systems 收购了 Fortron Bioscience, Inc.,该公司主营单克隆和多克隆抗体、抗原和其他生物试剂的开发和生产。通过此次收购,我们还收购了 BiosPacific, Inc.,该公司为全球商业诊断行业供应免疫试剂,擅长通过合作的方式,从可行性检测到生产阶段,为客户提供支持。此次收购增强了 R&D Systems 为诊断行业提供服务的能力。2007 年 7 月,Fortron 并入 R&D Systems 生物技术部门。2011 年 4 月,R&D Systems 收购了 Boston Biochem, Inc. 的资产,该公司开发并生产创新性的泛素相关研究产品,处于全球领先地位。Boston Biochem 成立于 1997 年,专营泛素和类泛素蛋白以及相关酶、底物、抑制剂和试剂盒的若干相关产品系列。这些专业产品促进并加速了生物医学研究和新药研发工作。
 

R&D Systems European office

R&D Systems Europe

此外,在 2011 年 4 月,R&D Systems 和 R&D Systems Europe 收购了 Tocris Holdings Limited 及其子公司,该公司是为生命科学研究提供药理学试剂的领先供应商。Tocris 试剂包括生物活性肽和小分子,旨在调节受体、离子通道和一系列细胞内信号分子的活性。这些产品受到各领域生物医学研究人员的广泛关注。

L Gluatmic Acid

Tocris Bioscience 产品左旋谷氨酸的分子结构。

2013 年,我们收购了 Bionostics,进一步巩固并发展了我们的临床质控品部门;Bionostics 是世界领先的校准品和质控品开发商及制造商,其产品主要面向原始设备制造商。该公司总部位于马萨诸塞州德文斯,专门从事血糖和血气检测产品,主要用于重症监护和医疗护理点。

如今,我们的产品线已扩展到 24,000 多种产品,其中 95% 由集团内部工厂生产。在保持我们在细胞因子和免疫分析方面的核心优势的同时,我们还开发了抗体、细胞选择和多色流式细胞检测试剂盒,多重分析、生物活性化合物和干细胞产品及其试剂盒,我们的临床血液学实验室拥有业内最丰富齐全的仪器。公司将其多样化的专业知识和产品组合优势带到研究和诊断领域,提供推动生命科学研究和支持临床突破所需的资源。

Diagnostics Division

Bio-Techne 诊断部检测实验室